DBV Technologies SA has announced the full exercise of its ABSA Warrants and BS Warrants issued as part of its March 2025 financing, resulting in gross proceeds of €166.7 million. The exercise involved 34,090,004 warrants attached to new ordinary shares, further strengthening the company's financial position. Following this transaction, DBV Technologies states it is sufficiently funded to support operations and prepare for the potential U.S. launch of the VIASKIN® Peanut patch for children aged 4 to 7, pending regulatory approval. The new shares will be admitted to trading on Euronext Paris under the same ISIN code and symbol as existing shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001159723-en) on January 16, 2026, and is solely responsible for the information contained therein.
Comments